Encouragingly in this respect, molecular signatures have been reported to accurately predict anti-TNF treatment response, but with distinct DNA methylation and transcriptomic profiles for RA patients treated with adalimumab and etanercept (36). This evidence concerns the gene TNF and rheumatoid arthritis.